Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide Sandoz is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple Myeloma: improves progression‑free and overall survival in patients who have received prior therapy. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and may improve blood counts. - Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: lowered platelet levels, raising bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach, sometimes with vomiting. - Diarrhea: loose stools, may lead to dehydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: profound immune suppression, risk of serious infection. - Infections: opportunistic or severe bacterial, viral, or fungal infections. - Second primary malignancies: emergence of new cancers unrelated to original disease. - Embryo‑fetal toxicity: teratogenic effects leading to birth defects. - Hypersensitivity reactions: anaphylaxis or severe skin reactions.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy: contraindicated; category X due to high risk of fetal harm. - Thromboembolism: assess risk factors and consider prophylactic anticoagulation. - Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. - Renal impairment: dose adjustment may be needed based on renal function. - Store below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Antiplatelet agents (e.g., aspirin): additive bleeding risk. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., statins): monitor for altered plasma levels. - NSAIDs: may exacerbate gastrointestinal irritation. - Hormonal contraceptives: reduced efficacy, advise alternative contraception. - Immunosuppressants (e.g., cyclosporine): monitor for additive immunosuppression. - Vaccines (non‑live): assess immune response, may require timing adjustments.